Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice

Sponsor
The First Affiliated Hospital with Nanjing Medical University
Study ID
NCT04094051
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ibrutinib — DRUG
    In the retrospective period, clinical information of approximate 500 patients with CLL/SLL prior to the study initiation will be collected retrospectively through chart review. There will be one time follow-up to collect data on disease progression, survival status and patient-reported outcomes.

Study Details

This is a non-interventional, Phase 4 study designed to improve understanding of current clinical practice in the treatment of CLL/SLL and to describe treatment pattern and evaluate outcomes of ibrutinib-treated CLL patients in China. This study will include both retrospective and prospective data collection.

Key Dates

Start date
Oct 1, 2019
Status verified
Sep 2019
Primary completion
Dec 31, 2020
Completion
Dec 31, 2021

Study Design

Enrollment
580 participants (estimated)

Primary Outcome Measure

Patient and disease characteristics [ Time Frame: Up to 10 years ]

Central Contacts

Related Studies